Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 26, Issue 9, Pages 1808-1812
Publisher
Oxford University Press (OUP)
Online
2015-06-19
DOI
10.1093/annonc/mdv266
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent developments in the implementation of novel designs for early-phase combination studies
- (2015) N. A. Wages et al. ANNALS OF ONCOLOGY
- A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials
- (2014) A. Doussau et al. ANNALS OF ONCOLOGY
- Designs of drug-combination phase I trials in oncology: a systematic review of the literature
- (2014) M.- K. Riviere et al. ANNALS OF ONCOLOGY
- Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey
- (2014) Xavier Paoletti et al. EUROPEAN JOURNAL OF CANCER
- Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
- (2014) Sophie Postel-Vinay et al. EUROPEAN JOURNAL OF CANCER
- Adaptive Dose-Finding Studies: A Review of Model-Guided Phase I Clinical Trials
- (2014) Alexia Iasonos et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response to comments on ‘Competing designs for drug combination in phase I dose-finding clinical trials’ by G. Yin, R. Lin and N. Wages
- (2014) Marie-Karelle Riviere et al. STATISTICS IN MEDICINE
- Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials
- (2013) Arif Manji et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials
- (2013) Adélaïde Doussau et al. STATISTICS IN MEDICINE
- Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials
- (2012) S. Gupta et al. JNCI-Journal of the National Cancer Institute
- Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents
- (2012) Christophe Le Tourneau et al. PLoS One
- Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading
- (2011) Emily M. Van Meter et al. STATISTICS IN MEDICINE
- Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities
- (2011) Mei-Yin C. Polley STATISTICS IN MEDICINE
- Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials
- (2010) Christophe Le Tourneau et al. JOURNAL OF CLINICAL ONCOLOGY
- A systematic methodology review of phase I radiation dose escalation trials
- (2010) Madelon Pijls-Johannesma et al. RADIOTHERAPY AND ONCOLOGY
- Dose Escalation Methods in Phase I Cancer Clinical Trials
- (2009) Christophe Le Tourneau et al. JNCI-Journal of the National Cancer Institute
- A comparison of model choices for the continual reassessment method in phase I cancer trials
- (2009) X. Paoletti et al. STATISTICS IN MEDICINE
- A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies
- (2008) Alexia Iasonos et al. Clinical Trials
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started